Why Is INHIBRX BIOSCIENCES (INBX) Stock Down Today?
By the Top Tier Newswire AI Desk · September 8, 2026 at 11:21 AM ET · reviewed against 5 wire stories
INHIBRX BIOSCIENCES (INBX) is down -11.24% in the latest session. Our newswire has captured 5 stories on INBX across 5 sources in the last 36 hours, with AI sentiment reading bullish (avg 72/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why INBX stock is down today
Inhibrx Biosciences (INBX) fell 11.24% to $107.55 in morning trading after a sharp intraday reversal from a session high of $137.25. The stock opened with a modest 1.5% gap up from the prior close but reversed course following the release of positive Phase 2 trial data for its cancer therapy INBRX-106 combined with Merck’s Keytruda. The data showed a 48.3% clinical overall response rate (cORR) and 72.4% of patients remaining progression-free at six months, compared to 26.5% and 42.8% for monotherapy.
What Happened
The company announced that INBRX-106, the first OX40 agonist to demonstrate clinical benefit in a randomized study, achieved an interim median progression-free survival (PFS) of 9.6 months in the head and neck squamous cell carcinoma (HNSCC) trial. The results were disclosed in a PR Newswire release and highlighted by multiple outlets, including Seeking Alpha and The Fly. Earlier in the week, Inhibrx shares had risen 6% following similar positive data. However, the stock’s sharp intraday decline suggests that the market may have overreacted to the initial positive open and subsequent news.
What The Data Shows
The stock opened at $123.00 and reached a high of $137.25 before falling to a session low of $94.00. Volume so far is 0.7 million shares, or 1.9 times the 3-month average. The stock has traded between $26.19 and $155.29 over the past 52 weeks and currently has a market cap of $1.8 billion. Despite the recent data, the company remains unprofitable with a TTM EPS of -8.88 and a TTM revenue decline of 100.0%. The stock has also printed one fresh 52-week low on September 8.
What To Watch
Investors should monitor the webcast on September 8 at 5:00 a.m. PT, where Inhibrx will present full Phase 2 results for INBRX-106. Coverage breadth and market reaction to the presentation will be key indicators of the stock’s near-term trajectory.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
INBX · Sep 8 session (5-min) · -1.79% vs prior close · updated 9:00 PM ETAI sentiment, last 36h · averaged over 5 stories · 72/100 bullish
The headlines behind the move
Story flow · 5 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoSeeking AlphaBULLISH 73Product/PR
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Inhibrx Biosciences (INBX) stock gains as cancer therapy INBRX-106 with Merck (MRK) Keytruda outperforms the blockbuster drug in a mid-stage trial. Read more here.
5d agoInvestorsHubBULLISH 67Product/PR
Inhibrx Shares Rise After Positive Phase 2 Head and Neck Cancer Data
Inhibrx shares rose 6% after Phase 2 data showed higher response rates for INBRX-106 plus pembrolizumab in head and neck cancer.
5d agoInvesting.com MarketsBULLISH 73Product/PR
Inhibrx stock jumps on positive cancer drug trial results
Inhibrx stock jumps on positive cancer drug trial results
5d agoThe FlyBULLISH 73Product/PR
Inhibrx’s INBRX-106 achieves clinical benefit in Phase 2 HNSCC study
5d agoPR NewswireBULLISH 76Product/PR
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
First OX40 agonist to demonstrate clinical benefit in a randomized study INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression free at 6 months, compared with 26.5% and 42.8% for pembrolizumab alone Results are most pronounced in HPV+ patients, with...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →